What Clinical Evidence Supports Neuronox for Glabellar Lines?

A published Phase III clinical trial evaluated a botulinum toxin type A preparation referred to in the paper as NBoNT in adults with moderate-to-severe glabellar wrinkles. [1]

The study is particularly relevant to the aesthetic evidence base because it was:

• prospective;

• randomized;

• double-blind;

• active-controlled;

• multicenter; and

• Phase III.

A total of 314 participants were randomized in a 1:1 ratio to receive either NBoNT or onabotulinumtoxinA.

Both groups received 20 U under the study protocol. [1]

At the primary assessment at week 4, the investigator-assessed responder rate at maximum frown was:

NBoNT: 93.7% (133/142)

versus

OnabotulinumtoxinA: 94.5% (138/146).

The study confirmed non-inferiority of NBoNT for its primary comparison. [1]

What Question Was the Trial Designed to Answer?

The trial was not designed primarily to determine whether NBoNT was superior to onabotulinumtoxinA.

Instead, it asked whether NBoNT could demonstrate efficacy that was non-inferior to the active comparator for moderate-to-severe glabellar wrinkles under the defined study protocol. [1]

This distinction is fundamental.

A superiority trial asks whether one treatment produces a statistically superior result.

A non-inferiority trial asks whether the new treatment is not unacceptably worse than the active comparator by more than a prespecified statistical margin.

Therefore, the principal evidence statement from this trial should remain:

NBoNT met the study's prespecified non-inferiority criterion.

It should not be rewritten as:

“Neuronox was better than onabotulinumtoxinA.”

Who Was Studied?

The trial enrolled adults with moderate-to-severe glabellar wrinkles at maximum frown. [1]

The study population was therefore specifically selected for visible dynamic glabellar-line severity.

This matters when applying the evidence.

The trial provides evidence for the population and aesthetic concern studied; it does not automatically establish efficacy for every facial area, every wrinkle type or every injection pattern.

How Was the Study Designed?

The study used a double-blind, randomized, active-controlled Phase III design. [1]

Randomization helps reduce systematic differences between treatment groups.

Double blinding reduces the risk that knowledge of treatment assignment influences clinical assessment or participant perception.

An active comparator allows the investigational treatment to be evaluated against an established BoNT-A treatment rather than only against placebo.

The multicenter design also means that the study was not conducted solely at one clinical site.

Together, these features strengthen the internal clinical relevance of the comparison, although no individual design feature eliminates every potential source of bias.

What Dose Was Studied?

Participants were randomized 1:1 to receive 20 U of toxin. [1]

This point must be interpreted carefully.

The study provides evidence for the 20-U protocol actually investigated in this trial.

It should not be converted into a universal rule that the labeled units of all BoNT-A products are interchangeable.

Botulinum toxin potency units are product-specific, and dose relationships observed in one head-to-head trial should remain connected to the products, indication and protocol actually studied.

What Was the Primary Endpoint?

The primary endpoint was the responder rate according to investigator live assessment at maximum frown at week 4. [1]

This is important because the often-quoted 93.7% figure is not a general statement that “93.7% of patients were satisfied” or that “93.7% had no wrinkles.”

It refers specifically to the responder definition used by the study and assessed by the investigator at maximum frown at the prespecified week-4 time point.

Evidence-based communication should preserve that context.

What Was the Main Result?

At four weeks after treatment, responder rates at maximum frown were:

NBoNT: 93.7% (133/142)

OnabotulinumtoxinA: 94.5% (138/146) [1]

The trial's statistical analysis confirmed non-inferiority of NBoNT.

The numerical difference between the responder rates was small, but the scientific conclusion should be based on the prespecified statistical analysis rather than on visual inspection of the percentages alone.

The correct interpretation is that NBoNT satisfied the trial's non-inferiority criterion under the studied conditions.

What Happened Beyond Week 4?

The study did not stop assessing efficacy after the primary week-4 endpoint.

Secondary endpoints included investigator live assessments at weeks 8, 12 and 16, both during frowning and at rest. [1]

The study also included photographic assessment by a blinded panel at week 4 and evaluated subjective satisfaction.

According to the published abstract, no significant difference between groups was found for any secondary efficacy variable at any assessed time point. [1]

This adds context to the primary result because the comparison was not based solely on one observation at week 4.

However, the primary endpoint remains the central prespecified efficacy analysis and should not be replaced by secondary outcomes.

Did the Study Assess Patient Satisfaction?

Yes.

Subjective satisfaction scores were included among the study's secondary assessments. [1]

This is relevant because aesthetic outcomes are not purely investigator-defined; patient perception is also clinically meaningful.

However, satisfaction should be treated as a distinct outcome rather than merged with the investigator-assessed responder rate.

A responder rate and a satisfaction score answer different questions.

What Did the Trial Report About Safety?

The publication reported that there were no serious adverse effects with either toxin and described both treatments as well tolerated within the trial. [1]

This is useful product-specific safety information, but its interpretation should remain bounded by:

• the studied population;

• the studied dose;

• the glabellar treatment protocol;

• the study duration; and

• the number of participants.

The result does not establish that serious adverse events can never occur with Neuronox or other BoNT-A products.

It also does not establish universal safety superiority over the comparator.

Why Is 93.7% an Important Number—but Also an Easy Number to Misuse?

The figure is clinically interesting because it represents a high responder rate in the studied population at the primary week-4 assessment.

But it is easy to strip the number from its scientific definition.

The accurate statement is:

At week 4, 93.7% (133/142) of evaluated participants in the NBoNT group met the study's investigator-assessed responder definition at maximum frown. [1]

Less accurate statements would include:

“Neuronox works in 93.7% of everyone.”

“93.7% of patients become wrinkle-free.”

“Neuronox has a 93.7% satisfaction rate.”

Those statements change what the endpoint actually measured.

What Does “Non-Inferior” Mean in This Trial?

Non-inferiority is often misunderstood as a softer way of saying “equal.”

It is not.

The trial established a statistical framework before interpreting the comparison.

The goal was to determine whether the efficacy of NBoNT was not worse than that of the active comparator beyond the acceptable margin specified by the study.

Because the prespecified criterion was satisfied, the study supported non-inferiority.

That does not establish:

• superiority;

• identical molecular properties;

• identical clinical behavior in every patient;

• universal dose interchangeability; or

• equivalence across all aesthetic indications.

The finding belongs to the specific trial in which it was demonstrated.

Why Does This Trial Matter for Neuronox?

For Neuronox, this study is particularly relevant because it provides product-specific randomized Phase III evidence in an aesthetic indication rather than relying only on general BoNT-A pharmacology. [1]

It allows several concrete statements to be made:

The product was studied in a randomized Phase III comparison.

The trial included 314 randomized participants.

A 20-U treatment was studied.

The primary endpoint was assessed at week 4.

The observed responder rate was 93.7% in the NBoNT group versus 94.5% with onabotulinumtoxinA.

The prespecified non-inferiority analysis was met. [1]

These statements are substantially more informative than a nonspecific claim that Neuronox is simply “effective.”

Does the Study Prove That Neuronox Is Better?

No.

The trial was designed to demonstrate non-inferiority, not superiority. [1]

A numerically higher or lower result at an individual endpoint should not be promoted as superiority unless the study was designed and statistically analyzed to support that conclusion.

In this trial, the primary week-4 responder rate was numerically slightly lower for NBoNT than for onabotulinumtoxinA, while the overall statistical conclusion was non-inferiority.

The appropriate evidence-based language is therefore:

“The Phase III trial demonstrated non-inferiority for the prespecified primary endpoint.”

Can This Trial Be Used to Claim That the Products Are Interchangeable?

No.

The trial provides evidence for a specific head-to-head comparison using the studied products, dose and glabellar-line protocol.

It does not prove universal interchangeability between BoNT-A products.

This distinction is particularly important because potency units are product-specific.

A studied 1:1 numerical unit comparison should not automatically become a universal conversion rule for other brands, muscles or indications.

What Are the Important Limitations?

Several boundaries should be kept in mind when interpreting the trial.

First, the study evaluated one aesthetic indication: moderate-to-severe glabellar wrinkles.

Second, it evaluated a defined 20-U treatment protocol.

Third, the primary endpoint was assessed at week 4, although secondary assessments extended through week 16.

Fourth, the results come from the specific study population and should not automatically be generalized to every demographic or clinical setting.

Finally, the publication disclosed industry sponsorship and an author-employment relationship. [1]

These disclosures do not invalidate the randomized, double-blind study, but they are relevant when assessing the evidence alongside study design, reporting and independent replication.

What Did the Study Disclose About Sponsorship?

The publication states that the trial was sponsored by the product manufacturer and that one author was an employee of the sponsor. [1]

For evidence appraisal, this information should be retained.

The appropriate response to industry sponsorship is neither to dismiss the study automatically nor to ignore the disclosure.

Instead, readers should evaluate the trial methodology, prespecified endpoints, statistical design, reporting completeness and consistency with the wider evidence base.

Bottom Line

The randomized Phase III glabellar-lines trial provides direct aesthetic clinical evidence for Neuronox/NBoNT.

Among 314 randomized participants, both groups received 20 U under the study protocol.

At the primary week-4 assessment, responder rates at maximum frown were:

93.7% with NBoNT

versus

94.5% with onabotulinumtoxinA. [1]

The trial met its prespecified non-inferiority criterion, secondary efficacy assessments did not show significant between-group differences at the evaluated time points, and no serious adverse effects were reported with either treatment. [1]

The evidence therefore supports a precise conclusion:

Neuronox has published randomized Phase III evidence in moderate-to-severe glabellar lines, with the primary efficacy analysis demonstrating non-inferiority to the active comparator under the studied protocol.

That is a meaningful product-specific evidence statement without converting non-inferiority into superiority.

Reference

1. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.